NASDAQ:MAPP - MAP Pharmaceuticals Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MAP Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileEarningsFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email MAP Pharmaceuticals, Inc, incorporated on July 3, 2003, is a development-stage company. As of December 31, 2011, the Company was focusing to advance its product candidate, LEVADEX (MAP0004) orally inhaled migraine therapy, which is an orally inhaled version of dihydroergotamine mesylate (DHE), for the acute treatment of migraine. The Company had completed clinical development for LEVADEX in 2011 and submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA). Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:MAPP Previous Symbol CUSIPN/A CIK1401923 WebN/A Phone+1-302-6587581Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive MAPP News and Ratings via Email Sign-up to receive the latest news and ratings for MAPP and its competitors with MarketBeat's FREE daily newsletter. MAP Pharmaceuticals (NASDAQ:MAPP) Frequently Asked Questions What is MAP Pharmaceuticals' stock symbol? MAP Pharmaceuticals trades on the NASDAQ under the ticker symbol "MAPP." Has MAP Pharmaceuticals been receiving favorable news coverage? News stories about MAPP stock have been trending neutral this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. MAP Pharmaceuticals earned a media sentiment score of 0.3 on InfoTrie's scale. They also assigned news headlines about the healthcare company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the next few days. View News Stories for MAP Pharmaceuticals. How can I contact MAP Pharmaceuticals? MAP Pharmaceuticals' mailing address is 2525 Dupont Dr, IRVINE, CA 92612-1531, United States. The healthcare company can be reached via phone at +1-302-6587581. MarketBeat Community Rating for MAP Pharmaceuticals (NASDAQ MAPP)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 87 (Vote Outperform)Underperform Votes: 75 (Vote Underperform)Total Votes: 162MarketBeat's community ratings are surveys of what our community members think about MAP Pharmaceuticals and other stocks. Vote "Outperform" if you believe MAPP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MAPP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2020 by MarketBeat.com StaffFeatured Article: What is Depreciation?